The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Liquamar     2-hydroxy-3-(1- phenylpropyl)chromen-4-one

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Falithrom


Psychiatry related information on Falithrom

  • After 130 patients had electively received a femoropopliteal vein graft, they were randomly assigned to a therapy group (treatment with phenprocoumon [n = 66]) or to a control group (n = 64) that remained without any anticoagulant treatment [5].

High impact information on Falithrom


Chemical compound and disease context of Falithrom


Biological context of Falithrom


Anatomical context of Falithrom


Associations of Falithrom with other chemical compounds


Gene context of Falithrom


Analytical, diagnostic and therapeutic context of Falithrom

  • Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial [2].
  • In patients with preserved liver function occlusion of the shunt may be prevented by phenprocoumon treatment in the first 3 months after TIPSS placement [2].
  • Weekly management with phenprocoumon led to a 6.5% improvement (95% CI, 0.0%-13.1%) in time in the international normalized ratio target range when patients were managed at an anticoagulation clinic and to an 8.7% improvement (95% CI, 1.6%-15.9%) when patients were self-managed [31].
  • Weekly management of OAT with long-acting phenprocoumon has to be preferred at anticoagulation clinics or, where possible, through patient self-management [31].
  • METHODS: We conducted a population-based cohort study among patients of an anticoagulation clinic who were treated with acenocoumarol or phenprocoumon between April 1, 1991, and May 31, 2003, and whose CYP2C9 status was known [32].


  1. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Breddin, K., Loew, D., Lechner, K., Oberla, K., Walter, E. Circulation (1980) [Pubmed]
  2. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial. Sauer, P., Theilmann, L., Herrmann, S., Bruckner, T., Roeren, T., Richter, G., Stremmel, W., Stiehl, A. Hepatology (1996) [Pubmed]
  3. Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation. Wuillemin, W.A., Zenhäusern, R., Bernhard, M.C., Lämmle, B. Am. J. Med. (1997) [Pubmed]
  4. Decreased serum osteocalcin levels in phenprocoumon-treated patients. Pietschmann, P., Woloszczuk, W., Panzer, S., Kyrle, P., Smolen, J. J. Clin. Endocrinol. Metab. (1988) [Pubmed]
  5. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Kretschmer, G., Herbst, F., Prager, M., Sautner, T., Wenzl, E., Berlakovich, G.A., Zekert, F., Marosi, L., Schemper, M. Archives of surgery (Chicago, Ill. : 1960) (1992) [Pubmed]
  6. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Bertina, R.M., Ploos van Amstel, H.K., van Wijngaarden, A., Coenen, J., Leemhuis, M.P., Deutz-Terlouw, P.P., van der Linden, I.K., Reitsma, P.H. Blood (1990) [Pubmed]
  7. Phenylbutazone and sulfinpyrazone interaction with oral anticoagulant phenprocoumon. O'Reilly, R.A. Arch. Intern. Med. (1982) [Pubmed]
  8. VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement. Schalekamp, T., Brassé, B.P., Roijers, J.F., van Meegen, E., van der Meer, F.J., van Wijk, E.M., Egberts, A.C., de Boer, A. Clin. Pharmacol. Ther. (2007) [Pubmed]
  9. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Schalekamp, T., Oosterhof, M., van Meegen, E., van Der Meer, F.J., Conemans, J., Hermans, M., Meijerman, I., de Boer, A. Clin. Pharmacol. Ther. (2004) [Pubmed]
  10. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans. Heimark, L.D., Toon, S., Gibaldi, M., Trager, W.F., O'Reilly, R.A., Goulart, D.A. Clin. Pharmacol. Ther. (1987) [Pubmed]
  11. A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization. Omran, H., Hammerstingl, C., Schmidt, H., von der Recke, G., Paar, W.D., Lüderitz, B. Thromb. Haemost. (2003) [Pubmed]
  12. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Schaefer, C., Hannemann, D., Meister, R., Eléfant, E., Paulus, W., Vial, T., Reuvers, M., Robert-Gnansia, E., Arnon, J., De Santis, M., Clementi, M., Rodriguez-Pinilla, E., Dolivo, A., Merlob, P. Thromb. Haemost. (2006) [Pubmed]
  13. Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study. Breddin, K., Loew, D., Lechner, K., Uberla, K., Walter, E. Thromb. Haemost. (1979) [Pubmed]
  14. Reduction of migrainous headaches during the use of acenocoumarol. van Puijenbroek, E.P., Egberts, A.C., Trooster, J.F., Zomerdijk, J. Headache. (1996) [Pubmed]
  15. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Meinertz, T., Gilfrich, H.J., Groth, U., Jonen, H.G., Jähnchen, E. Clin. Pharmacol. Ther. (1977) [Pubmed]
  16. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Jähnchen, E., Meinertz, T., Gilfrich, H.J., Groth, U., Martini, A. Clin. Pharmacol. Ther. (1976) [Pubmed]
  17. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Penning-van Beest, F.J., van Meegen, E., Rosendaal, F.R., Stricker, B.H. Clin. Pharmacol. Ther. (2001) [Pubmed]
  18. Stereochemical aspects of the metabolism of phenprocoumon in rat liver microsomes. Wheeler, C., Trager, W.F., Porter, W.R. Biochem. Pharmacol. (1981) [Pubmed]
  19. Vitamin K metabolism and vitamin K1 status in human liver samples: a search for inter-individual differences in warfarin sensitivity. Thijssen, H.H., Drittij-Reijnders, M.J. Br. J. Haematol. (1993) [Pubmed]
  20. Metabolic fate of phenprocoumon in humans. Toon, S., Heimark, L.D., Trager, W.F., O'Reilly, R.A. Journal of pharmaceutical sciences. (1985) [Pubmed]
  21. Liver damage induced by coumarin anticoagulants. Ehrenforth, S., Schenk, J.F., Scharrer, I. Semin. Thromb. Hemost. (1999) [Pubmed]
  22. Endoscopic finding of an intramural haemorrhage in the duodenum under anticoagulant therapy with phenprocoumon. Botzler, R., Wagner, T., Ritter, U. Endoscopy. (1986) [Pubmed]
  23. Pharmacogenetics of oral anticoagulants. Daly, A.K., King, B.P. Pharmacogenetics (2003) [Pubmed]
  24. Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure. Schimanski, C.C., Burg, J., Möhler, M., Höhler, T., Kanzler, S., Otto, G., Galle, P.R., Lohse, A.W. J. Hepatol. (2004) [Pubmed]
  25. Circulating osteocalcin during oral anticoagulant therapy. van Haarlem, L.J., Knapen, M.H., Hamulyák, K., Vermeer, C. Thromb. Haemost. (1988) [Pubmed]
  26. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Ufer, M., Svensson, J.O., Krausz, K.W., Gelboin, H.V., Rane, A., Tybring, G. Eur. J. Clin. Pharmacol. (2004) [Pubmed]
  27. Selective binding of coumarin enantiomers to human alpha1-acid glycoprotein genetic variants. Hazai, E., Visy, J., Fitos, I., Bikádi, Z., Simonyi, M. Bioorg. Med. Chem. (2006) [Pubmed]
  28. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Ufer, M. Clinical pharmacokinetics. (2005) [Pubmed]
  29. A simplified functional assay for protein C in plasma samples. Thiel, W., Preissner, K.T., Delvos, U., Müller-Berghaus, G. Blut (1986) [Pubmed]
  30. Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism. Kammerer, B., Kahlich, R., Ufer, M., Laufer, S., Gleiter, C.H. Anal. Biochem. (2005) [Pubmed]
  31. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Gadisseur, A.P., Breukink-Engbers, W.G., van der Meer, F.J., van den Besselaar, A.M., Sturk, A., Rosendaal, F.R. Arch. Intern. Med. (2003) [Pubmed]
  32. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Visser, L.E., van Schaik, R.H., van Vliet, M., Trienekens, P.H., De Smet, P.A., Vulto, A.G., Hofman, A., van Duijn, C.M., Stricker, B.H. Clin. Pharmacol. Ther. (2005) [Pubmed]
WikiGenes - Universities